UCB and Baylor College of Medicine enter neurodegeneration alliance

Published: 9-Feb-2016
Research & Development

They will collaborate to discover transformational therapies for people with neurodegenerative disease


Belgian biopharmaceutical firm UCB has entered into a research agreement with Baylor College of Medicine in Houston, Texas, US that aims to discover new therapeutics to treat neurodegenerative disease.

Led by Professor Huda Zoghbi, a professor in the Departments of Paediatrics, Molecular and Human Genetics, Neurology and Neuroscience at Baylor College of Medicine, investigator at the Howard Hughes Medical Institute and the director of the Jan and Dan Duncan Neurological Research Institute (NRI) at Texas Children's Hospital, the research programme will focus on the discovery of medicines targeting pathways with a high level of genetic and human validation.

Professor Zoghbi and her collaborators have world leading capabilities in using functional genetics in model organisms to identify therapeutic points of intervention for new medicines.

Ismail Kola, Executive Vice President, UCB & President, New Medicines, UCB said: 'We cannot accelerate discovery of transformational medicines and create value for patients if we work alone. That is why we have been creating super networks with high quality scientific partners, combining insights from patients with deep understanding of disease mechanisms.

'This strategic research alliance brings together Huda Zoghbi’s world class research with our high quality R&D teams to discover medicines based on genetically validated targets that could transform the lives of people living with severe neurodegenerative disease.'

  • Companies:
  • UCB
See more

You may also like

Ingredients

Therapeutics: dapirolizumab for systemic lupus erythematosus

Read more
Although there have been some advances in recent years, systemic lupus erythematosus (SLE) remains a significant unmet medical need

Trending Articles

  1. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  2. Thermo Fisher Scientific officially opens US oral solid dose testing and R&D facility The company's further expansion in the Bend, Oregon area will assist its pharmaceutical clients in the early development of oral solid dosage (OSD) forms
  3. BioMarin Pharmaceutical expands Cork targeted therapy manufacturing facility with new lab The Irish facility is responsible for the development and commercialisation of therapies that address genetic conditions, and this expansion will allow the company to enhance its approved medicine production capacity
  4. Medac and chiron develop organ-on chip tech for animal free drug testing The companies aim to develop an animal-free pharmaceutical testing method that utilises organ-on chip technology, and will be used in rheumatoid arthritis drug testing
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Parenteral preparations: formulation challenges Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are sterile preparations that are administrated directly into the systemic circulation of humans or animals

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Ingredients

Therapeutics: dapirolizumab for systemic lupus erythematosus

Although there have been some advances in recent years, systemic lupus erythematosus (SLE) remains a significant unmet medical need
Media

MRC forges two new deals with industry to speed drug discovery

Building on the MRC’s strong track record in establishing innovative collaborations with industry, the MRC has formed partnerships with two global pharmaceutical companies, UCB and AstraZeneca
Research & Development

Heptares joins consortium applying cryo-electron microscopy to structure-based drug discovery

Cryo-EM can reveal the structure of complex molecular assemblies to near atomic level
Regulatory

Leukaemia – inotuzumab ozogamicin

A handful of antibody-drug conjugates have now reached the market and plenty more are under development
Research & Development

Medical Research Council and UCB link up to offer access to UCB’s antibody discovery platform

MRC scientists will be able to assess more than one billion antibody producing B-cells
Research & Development

First results confirm drug discovery potential of the European Lead Factory

Two Qualified Hit Lists have been delivered
Research & Development

Vectura and UCB form inflammatory disease collaboration

Will focus on bringing to clinical proof-of-concept a UCB-generated biological therapy targeting a key molecule in the immune system
Subscribe now